Johnson & Johnson (JNJ) says it expects to incur a special charge in Q2 of ~$600M to increase its accrual for the potential settlement of previously disclosed civil litigation matters related to Risperdal, Invega, Natrecor and Omnicare (OCR).
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Benzinga.com (Feb 23, 2015)
at Nasdaq.com (Feb 19, 2015)
at Nasdaq.com (Feb 17, 2015)
at Nasdaq.com (Feb 10, 2015)
at Investor's Business Daily (Jan 20, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs